MX2016006625A - Receptores de células t humanas con alta afinidad modificados por medio de manipulación genética. - Google Patents

Receptores de células t humanas con alta afinidad modificados por medio de manipulación genética.

Info

Publication number
MX2016006625A
MX2016006625A MX2016006625A MX2016006625A MX2016006625A MX 2016006625 A MX2016006625 A MX 2016006625A MX 2016006625 A MX2016006625 A MX 2016006625A MX 2016006625 A MX2016006625 A MX 2016006625A MX 2016006625 A MX2016006625 A MX 2016006625A
Authority
MX
Mexico
Prior art keywords
tcrs
cell receptors
engineered
affinity
affinity human
Prior art date
Application number
MX2016006625A
Other languages
English (en)
Inventor
N Smith Sheena
M Kranz David
t harris Daniel
Original Assignee
Univ Illinois
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Illinois filed Critical Univ Illinois
Publication of MX2016006625A publication Critical patent/MX2016006625A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

Se proporcionan receptores de células T (TCR) que tienen mayor afinidad para el antígeno Survivina. Los TCR de alta afinidad se modificaron por medio de manipulación genética a través de la generación de bibliotecas de mutaciones de los TCR en formato de cadena simple, seguido por una selección para mejorar la estabilidad y afinidad en la superficie de levadura (es decir, evolución dirigida). En algunas realizaciones, los TCR modificados por medio de manipulación genética se pueden utilizar en forma soluble para la administración dirigida in vivo, o como genes introducidos en células T en un entorno de células T adoptivas.
MX2016006625A 2013-11-22 2014-11-21 Receptores de células t humanas con alta afinidad modificados por medio de manipulación genética. MX2016006625A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361907887P 2013-11-22 2013-11-22
PCT/US2014/066892 WO2015077607A1 (en) 2013-11-22 2014-11-21 Engineered high-affinity human t cell receptors

Publications (1)

Publication Number Publication Date
MX2016006625A true MX2016006625A (es) 2016-12-02

Family

ID=53180203

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2016006620A MX371202B (es) 2013-11-22 2014-11-21 Receptores de células t humanas con alta afinidad modificados por medio de manipulación genética.
MX2016006625A MX2016006625A (es) 2013-11-22 2014-11-21 Receptores de células t humanas con alta afinidad modificados por medio de manipulación genética.
MX2021006932A MX2021006932A (es) 2013-11-22 2016-05-20 Receptores de celulas t humanas con alta afinidad modificados por medio de manipulacion genetica.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2016006620A MX371202B (es) 2013-11-22 2014-11-21 Receptores de células t humanas con alta afinidad modificados por medio de manipulación genética.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021006932A MX2021006932A (es) 2013-11-22 2016-05-20 Receptores de celulas t humanas con alta afinidad modificados por medio de manipulacion genetica.

Country Status (20)

Country Link
US (4) US10344075B2 (es)
EP (2) EP3071593B1 (es)
JP (4) JP6697386B2 (es)
KR (2) KR20160085345A (es)
CN (2) CN105873945B (es)
AU (4) AU2014352834B2 (es)
BR (1) BR112016011567A2 (es)
CA (2) CA2930847A1 (es)
DK (1) DK3071593T3 (es)
ES (1) ES2729406T3 (es)
IL (2) IL245468B (es)
MX (3) MX371202B (es)
PL (1) PL3071593T3 (es)
PT (1) PT3071593T (es)
RU (2) RU2740648C2 (es)
SA (1) SA516371174B1 (es)
SG (2) SG10201804335QA (es)
TR (1) TR201908404T4 (es)
WO (2) WO2015077607A1 (es)
ZA (2) ZA201603116B (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009511637A (ja) 2005-10-17 2009-03-19 スローン−ケターリング インスティチュート フォー キャンサー リサーチ Ｈｌａクラスｉｉ結合ｗｔ１ペプチド及びその組成物、並びにその作成方法
EP3117836A1 (en) 2006-04-10 2017-01-18 Sloan Kettering Institute For Cancer Research Immunogenic wt-1 peptides and uses thereof
CN108676069A (zh) 2012-01-13 2018-10-19 纪念斯隆凯特林癌症中心 免疫原性wt-1肽及其使用方法
AU2014207615B2 (en) 2013-01-15 2018-11-01 Memorial Sloan Kettering Cancer Center Immunogenic WT-1 peptides and methods of use thereof
US10815273B2 (en) 2013-01-15 2020-10-27 Memorial Sloan Kettering Cancer Center Immunogenic WT-1 peptides and methods of use thereof
MX371202B (es) * 2013-11-22 2020-01-22 Univ Illinois Receptores de células t humanas con alta afinidad modificados por medio de manipulación genética.
EA201890772A1 (ru) * 2015-09-22 2018-10-31 Юлиус Максимилианс-Универзитет Вюрцбург Способ высокоуровневого и стабильного переноса генов в лимфоцитах
US20180305432A1 (en) * 2015-10-01 2018-10-25 Ospedale San Raffaele S.R.L. Tcr and uses thereof
GB201520570D0 (en) * 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
EP3394092A1 (en) 2015-12-23 2018-10-31 Fred Hutchinson Cancer Research Center High affinity t cell receptors and uses thereof
MA45491A (fr) * 2016-06-27 2019-05-01 Juno Therapeutics Inc Épitopes à restriction cmh-e, molécules de liaison et procédés et utilisations associés
WO2018090057A1 (en) * 2016-11-14 2018-05-17 Fred Hutchinson Cancer Research Center High affinity merkel cell polyomavirus t antigen-specific tcrs and uses thereof
SG11201908527SA (en) * 2017-03-15 2019-10-30 Hutchinson Fred Cancer Res High affinity mage-a1-specific tcrs and uses thereof
KR20200020681A (ko) * 2017-04-24 2020-02-26 오스페달레 산 라파엘 에스.알.엘. Tcr 및 펩티드
JP7181517B2 (ja) * 2018-01-23 2022-12-01 国立大学法人三重大学 Ｔ細胞レセプター
AU2019312200A1 (en) * 2018-07-23 2021-02-25 Heidelberg Pharma Research Gmbh Use of anti-CD137 antibody drug conjugate (ADC) in allogeneic cell therapy
GB201911066D0 (en) 2019-08-02 2019-09-18 Achilles Therapeutics Ltd T cell therapy
US20220409661A1 (en) * 2019-08-20 2022-12-29 Fred Hutchinson Cancer Research Center T-cell immunotherapy specific for wt-1
JP2023513706A (ja) * 2020-02-12 2023-04-03 アッヴィ・インコーポレイテッド 二特異性結合分子
CA3176654A1 (en) 2020-04-28 2021-11-04 Karl PEGGS T cell therapy
WO2022214835A1 (en) 2021-04-09 2022-10-13 Achilles Therapeutics Uk Limited Batch release assay for pharmaceutical products relating to t cell therapies
GB202109886D0 (en) 2021-07-08 2021-08-25 Achilles Therapeutics Uk Ltd Assay
KR20240023426A (ko) 2021-06-22 2024-02-21 아킬레스 테라퓨틱스 유케이 리미티드 항원-특이적 t 세포를 생산하는 방법
IL310204A (en) * 2021-07-19 2024-03-01 Univ Texas Peptides and engineered T cell receptors targeting FANCI, RAD51 and PBK antigens and methods of use

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3927193A (en) 1973-05-18 1975-12-16 Hoffmann La Roche Localization of tumors by radiolabelled antibodies
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4361544A (en) 1980-03-03 1982-11-30 Goldenberg Milton David Tumor localization and therapy with labeled antibodies specific to intracellular tumor-associated markers
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4444744A (en) 1980-03-03 1984-04-24 Goldenberg Milton David Tumor localization and therapy with labeled antibodies to cell surface antigens
US4348376A (en) 1980-03-03 1982-09-07 Goldenberg Milton David Tumor localization and therapy with labeled anti-CEA antibody
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4468457A (en) 1981-06-01 1984-08-28 David M. Goldenberg Method for producing a CSAp tryptic peptide and anti-CSAp antibodies
US5101827A (en) 1985-07-05 1992-04-07 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US4640561A (en) 1985-11-15 1987-02-03 Ford Motor Company Flexible printed circuit connector
US5059413A (en) 1988-04-18 1991-10-22 Xoma Corporation Scintigraphic monitoring of immunotoxins using radionuclides and heterobifunctional chelators
ATE172879T1 (de) 1989-08-09 1998-11-15 Rhomed Inc Direkte radioetikettierung von antikörpern und sonstigen proteinen mittels technetium oder rhenium
US5299253A (en) 1992-04-10 1994-03-29 Akzo N.V. Alignment system to overlay abdominal computer aided tomography and magnetic resonance anatomy with single photon emission tomography
US6699658B1 (en) 1996-05-31 2004-03-02 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
US6300065B1 (en) 1996-05-31 2001-10-09 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
US6696251B1 (en) 1996-05-31 2004-02-24 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
US6759243B2 (en) 1998-01-20 2004-07-06 Board Of Trustees Of The University Of Illinois High affinity TCR proteins and methods
ID28040A (id) 1998-05-19 2001-05-03 Avidex Ltd Reseptor sel t yang dapat larut
EP1124568B1 (en) 1998-10-21 2007-08-22 Altor BioScience Corporation Polyspecific binding molecules and uses thereof
EP1421115B1 (en) * 2001-08-31 2005-03-02 Avidex Limited Soluble t cell receptor
US7892559B2 (en) 2002-01-30 2011-02-22 Survac Aps Survivin-derived peptides and use thereof
US7569664B2 (en) 2002-10-09 2009-08-04 Immunocore Limited Single chain recombinant T cell receptors
GB0304068D0 (en) 2003-02-22 2003-03-26 Avidex Ltd Substances
GB0328363D0 (en) * 2003-12-06 2004-01-14 Imp College Innovations Ltd Therapeutically useful molecules
DK1765860T3 (da) 2004-05-19 2009-03-09 Immunocore Ltd Ny-ESO-T.cellereceptor med höj affinitet
EP1756278B1 (en) 2004-05-19 2008-09-17 MediGene Ltd. Method of improving t cell receptors
GB0524477D0 (en) 2005-11-30 2006-01-11 Avidex Ltd Isolated T cell receptors which specifically bind to vygfvracl-hla-24
GB0511124D0 (en) * 2005-06-01 2005-07-06 Avidex Ltd High affinity melan-a t cell receptors
AT503861B1 (de) 2006-07-05 2008-06-15 F Star Biotech Forsch & Entw Verfahren zur manipulation von t-zell-rezeptoren
US8088379B2 (en) 2006-09-26 2012-01-03 The United States Of America As Represented By The Department Of Health And Human Services Modified T cell receptors and related materials and methods
US9281917B2 (en) 2007-01-03 2016-03-08 Nokia Technologies Oy Shared control channel structure
US8697854B2 (en) * 2008-11-24 2014-04-15 Helmholtz Zentrum München Deutsches Forschungszentrum Für Gesundheit Und Umwelt Gmbh High affinity T cell receptor and use thereof
WO2010075417A1 (en) 2008-12-23 2010-07-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Survivin specific t cell receptor for treating cancer
AU2010210083C1 (en) 2009-02-09 2015-11-26 Helmholtz Zentrum Muenchen Deutsches Forschungszentrum Fuer Gesundheit Und Umwelt (Gmbh) Repertoire of allo-restricted peptide-specific T cell receptor sequences and use thereof
GB0911566D0 (en) 2009-07-03 2009-08-12 Immunocore Ltd T cell receptors
WO2011044186A1 (en) 2009-10-06 2011-04-14 The Board Of Trustees Of The University Of Illinois Human single-chain t cell receptors
BR112013003647A2 (pt) 2010-07-28 2017-11-07 Immunocore Ltd receptores de células t.
DK2618835T3 (en) 2010-09-20 2017-08-28 Biontech Cell & Gene Therapies Gmbh ANTIGEN-SPECIFIC T-CELL RECEPTORS AND T-CELL EPITOPES
BR112014027374B1 (pt) 2012-05-03 2022-05-31 Fred Hutchinson Cancer Research Center Método para gerar um receptor de células t (tcr) com afinidade aumentada
WO2014191465A1 (en) * 2013-05-28 2014-12-04 Møller Niels Iversen Peptides derived from lawsonia intracellularis and their use in vaccination
PL228457B1 (pl) 2013-08-30 2018-03-30 Univ Jagiellonski Tomograf hybrydowy TOF-PET/CT
MX371202B (es) 2013-11-22 2020-01-22 Univ Illinois Receptores de células t humanas con alta afinidad modificados por medio de manipulación genética.
JP6712261B2 (ja) 2014-08-04 2020-06-24 フレッド ハッチンソン キャンサー リサーチ センター Ｗｔ−１に特異的なｔ細胞免疫治療

Also Published As

Publication number Publication date
KR20160085345A (ko) 2016-07-15
JP2020007374A (ja) 2020-01-16
ES2729406T3 (es) 2019-11-04
KR20160087866A (ko) 2016-07-22
US10023625B2 (en) 2018-07-17
IL245467B (en) 2020-04-30
NZ719707A (en) 2020-09-25
SG10201804335QA (en) 2018-06-28
CN105873945A (zh) 2016-08-17
US20220396606A1 (en) 2022-12-15
IL245468A0 (en) 2016-06-30
JP2017501129A (ja) 2017-01-12
MX2016006620A (es) 2017-05-11
EP3071593A4 (en) 2017-05-03
BR112016011583A2 (pt) 2017-09-26
CN105899530B (zh) 2020-05-08
JP2017501130A (ja) 2017-01-12
ZA201603169B (en) 2020-05-27
JP6970724B2 (ja) 2021-11-24
IL245468B (en) 2020-10-29
PL3071593T3 (pl) 2019-11-29
WO2015077615A1 (en) 2015-05-28
AU2014352826A1 (en) 2016-05-26
IL245467A0 (en) 2016-06-30
US20160280756A1 (en) 2016-09-29
AU2014352826B2 (en) 2019-08-01
MX371202B (es) 2020-01-22
SA516371174B1 (ar) 2019-04-14
JP6697386B2 (ja) 2020-05-20
ZA201603116B (en) 2018-12-19
SG10201804330YA (en) 2018-07-30
CN105873945B (zh) 2020-07-17
PT3071593T (pt) 2019-06-27
AU2021202274A1 (en) 2021-05-06
JP2022023196A (ja) 2022-02-07
CA2930852C (en) 2024-01-23
CA2930852A1 (en) 2015-05-28
EP3071594A1 (en) 2016-09-28
EP3071594A4 (en) 2017-05-03
US10344075B2 (en) 2019-07-09
RU2729383C2 (ru) 2020-08-06
NZ719720A (en) 2020-09-25
US20160280755A1 (en) 2016-09-29
BR112016011567A2 (pt) 2017-10-24
DK3071593T3 (da) 2019-06-11
JP6476182B2 (ja) 2019-02-27
AU2014352834A1 (en) 2016-05-26
AU2019272003B2 (en) 2021-05-06
RU2016124163A (ru) 2017-12-27
KR102415259B1 (ko) 2022-06-30
RU2740648C2 (ru) 2021-01-19
MX2021006932A (es) 2021-07-07
TR201908404T4 (tr) 2019-07-22
RU2016124179A (ru) 2017-12-27
CA2930847A1 (en) 2015-05-28
EP3071593B1 (en) 2019-03-13
AU2019272003A1 (en) 2019-12-19
CN105899530A (zh) 2016-08-24
EP3071593A1 (en) 2016-09-28
US20190055298A1 (en) 2019-02-21
WO2015077607A1 (en) 2015-05-28
AU2014352834B2 (en) 2019-08-29

Similar Documents

Publication Publication Date Title
MX2021006932A (es) Receptores de celulas t humanas con alta afinidad modificados por medio de manipulacion genetica.
CY1123142T1 (el) Βελτιωμενες μεθοδοι για την παραγωγη θετων κυτταρικων θεραπειων
MX2017007138A (es) Metodos y composiciones para terapia celular adoptiva.
MA40253A (fr) Cellules modifiées pour thérapie cellulaire adoptive
WO2018132739A3 (en) T cell receptors that bind to ny-eso-1 and methods of use thereof
PH12014502418B1 (en) Enhanced affinity t cell receptors and methods for making the same
MX2019013498A (es) Receptor de antigeno quimerico y metodos para usarlo.
MX2020006689A (es) Composiciones de vcar y metodos de uso.
EA201590488A1 (ru) Способы модификации клеток-хозяев
EP4279579A3 (en) Methods and compositions for natural killer cells
MX2013008850A (es) Composiciones y metodos para tratar enfermedades cardiovasculares.
MY197851A (en) Antibody formulations
MX2014014337A (es) Metodo de produccion de alta concentracion de celulas madre.
MX2019012017A (es) Celulas modificadas que expresan antigeno de membrana especifico de prostata (psma) o una forma modificada del mismo y metodos relacionados.
MX2018014043A (es) Composiciones de cultivo celular con antioxidantes y metodos para la produccion de polipeptidos.
AU2016335217A8 (en) Antigen receptors and uses thereof
EP4295914A3 (en) Genetically-engineered drug resistant t cells and methods of using the same
MX2015011781A (es) Medio de cultivo celular y metodos de produccion de anticuerpos.
HRP20201177T1 (hr) Terapijsko cjepivo za liječenje dijabetesa tipa 1 kod djece, primjena staničnog sortera i metoda umnožavanja treg stanica za proizvodnju terapijskog cjepiva za liječenje dijabetesa tipa 1
MX2021001981A (es) Metodos para preparar un poloxamero para usar en medio de cultivo celular.
MX350159B (es) Inyecciones mejoradas.
MX365656B (es) Nuevas vacunas contra multiples subtipos del virus del dengue.
WO2016049510A3 (en) Cell-based targeted delivery of pseudonomas exotoxin